| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/28/1999 | WO1999003995A1 T-cell receptor beta-like protein |
| 01/28/1999 | WO1999003882A2 Human leukocyte calcium activated potassium channel polypeptide |
| 01/28/1999 | WO1999003506A1 Remedies for solid tumor containing wilms' tumor gene (wt1) expression inhibitors |
| 01/28/1999 | WO1999003504A1 Medicinal compositions for treating immunodeficiency diseases |
| 01/28/1999 | WO1999003498A1 USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY |
| 01/28/1999 | WO1999003489A2 Methods and compositions for regulating nuclear trafficking of proteins |
| 01/28/1999 | WO1999003486A1 Antacid and papain combination |
| 01/28/1999 | WO1999003483A1 Use of neurotoxin therapy for treatment of urologic and related disorders |
| 01/28/1999 | WO1999003478A1 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor |
| 01/28/1999 | WO1999003477A1 Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
| 01/28/1999 | WO1999003476A1 Treatment of diabetes with thiazolidinedione and sulphonylurea |
| 01/28/1999 | WO1999003473A1 Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
| 01/28/1999 | WO1999003469A1 Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (ssri) |
| 01/28/1999 | WO1999003453A1 Novel pharmaceutical formulation with controlled release of active substances |
| 01/28/1999 | WO1998045477A3 Methods for assessing cardiovascular status and compositions for use thereof |
| 01/28/1999 | WO1998044913A3 Compositions containing mkc-442 in combination with other antiviral agents |
| 01/28/1999 | WO1998040056A3 Pyrrolidine and thiazole derivatives with metallo-beta-lactamase inhibitory properties |
| 01/28/1999 | WO1998027932A3 Cerebellum and embryo specific protein |
| 01/28/1999 | CA2521392A1 Use of neurotoxin therapy for treatment of urologic and related disorders |
| 01/28/1999 | CA2298066A1 Methods and compositions for regulating nuclear trafficking of proteins |
| 01/28/1999 | CA2297133A1 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor |
| 01/28/1999 | CA2296666A1 T-cell receptor beta-like protein |
| 01/28/1999 | CA2296503A1 Medicinal compositions for treating immunodeficiency diseases |
| 01/28/1999 | CA2296468A1 Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (ssri) |
| 01/28/1999 | CA2295926A1 Methods for diagnosis and treating cancers, and methods for identifying pathogenic markers in a sample of normal cells |
| 01/28/1999 | CA2286357A1 Antacid and papain combination |
| 01/27/1999 | EP0893503A2 Regulator protein from Staphylococcus aureus |
| 01/27/1999 | EP0893502A2 GreA from Staphylococcus aureus |
| 01/27/1999 | EP0893501A2 Ferrichrome transport atp-binding protein |
| 01/27/1999 | EP0893500A2 BmrU gene from Staphylococcus aureus |
| 01/27/1999 | EP0893499A2 Tetracycline resistance protein from Staphylococcus aureus |
| 01/27/1999 | EP0893498A2 cDNA clone MY1 that encodes a novel human 7-transmembrane receptor |
| 01/27/1999 | EP0893496A2 Histidyl tRNA synthetase from Chlamydia trachomatis |
| 01/27/1999 | EP0893495A2 Isoleucyl tRNA synthetase from Chlamydia trachomatis |
| 01/27/1999 | EP0893494A2 Aspartyl tRNA synthetase from Chlamydia trachomatis |
| 01/27/1999 | EP0892807A1 Gene family associated with neurosensory defects |
| 01/27/1999 | EP0892643A1 Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
| 01/27/1999 | EP0892640A2 Enteric-coated pharmaceutical compositions of mycophenolate |
| 01/27/1999 | EP0892633A2 Use of inhibitors of the activity of retinoic acid for treating sensitive skin and/or acute damage induced by uv radiation |
| 01/27/1999 | EP0630254B1 Compositions for the Treatment of Dry Eye Syndrome |
| 01/27/1999 | CN1041798C Synergistic combination of substance with gastric acid secretion inhibiting effect and acid degradable antibiotic |
| 01/26/1999 | US5863944 Compounds and compositions for delivering active agents |
| 01/26/1999 | US5863938 Wound healing agent comprises pyruvate selected from the group consisting of pyruvic acid, pharmaceutically acceptable salts of pyruvic acid and mixtures thereof; antioxidant; mixture of saturated and unsaturated fatty acids |
| 01/26/1999 | US5863927 Dextromethorphan and an oxidase inhibitor for treating intractable conditions |
| 01/26/1999 | US5863922 An analgesics mixture comprising acetaminophen, sedative butalbital and a n-methyl-d-aspartate receptor antagonist selected from dextrorphan, dextromethorphan |
| 01/26/1999 | US5863912 Method of treatment of hormone-unresponsive metastiatic prostate cancer |
| 01/26/1999 | US5863901 Use of bradykinin antagonists for the production of pharmaceuticals for the treatment of chronic fibrogenetic liver disorders and acute liver disorders |
| 01/26/1999 | US5863795 Nucleic acids that encode peptides which modulate apoptosis |
| 01/26/1999 | US5863780 A polynucleotide sequence encodes human protein kinase polypeptide; culture product |
| 01/26/1999 | US5863779 UBC7-like ubiquitin-conjugating enzyme |
| 01/26/1999 | US5863777 DNA encoding alanyl tRNA synthetase from streptococcus pneumonine |
| 01/26/1999 | US5863766 Isolated, pure polynucleotide encoding a polypeptide for treating vesicle trafficking, immunological, and neoplastic disorders. |
| 01/26/1999 | US5863762 Screening for antifungal agents |
| 01/26/1999 | US5863755 Nucleic acid encoding novel receptor-type phosphotyrosine phosphatase-κ |
| 01/26/1999 | US5863735 Human transmembrane 4 superfamily protein |
| 01/26/1999 | US5863563 Administering a ph-raising buffer in powder form |
| 01/26/1999 | US5863560 Compositions and methods for topical application of therapeutic agents |
| 01/26/1999 | US5863558 Administering a controlled release antiepileptic drug wherein the dosage form comprising a nonionic protective film for protecting from fluid of the gastrointestinal environment |
| 01/25/1999 | CA2238664A1 Novel regulator |
| 01/25/1999 | CA2238655A1 Cdna clone my1 that encodes a novel human 7-transmembrane receptor |
| 01/24/1999 | CA2238658A1 Novel grea |
| 01/23/1999 | CA2238682A1 Novel asps |
| 01/23/1999 | CA2238677A1 Novel iles |
| 01/23/1999 | CA2238674A1 Novel tetracycline resistance protein |
| 01/23/1999 | CA2238671A1 Novel bmru |
| 01/23/1999 | CA2238667A1 Novel ferrichrome transport atp-binding protein |
| 01/23/1999 | CA2238665A1 Novel reductase |
| 01/23/1999 | CA2238663A1 Novel hiss |
| 01/23/1999 | CA2238611A1 Novel lyss |
| 01/23/1999 | CA2238608A1 Novel cyss |
| 01/21/1999 | WO1999002680A1 New human growth regulator protein |
| 01/21/1999 | WO1999002678A1 Wa545 compositions |
| 01/21/1999 | WO1999002675A1 G-coupled receptor showing selective affinity for atp |
| 01/21/1999 | WO1999002665A1 Nanocrystalline formulations of human immunodeficiency virus (hiv) protease inhibitors using cellulosic surface stabilizers and methods of making such formulations |
| 01/21/1999 | WO1999002565A2 Agent for the treatment and/or prophylaxis of microcirculation disorders |
| 01/21/1999 | WO1999002561A1 Human f11 antigen: a cell surface receptor involved in platelet aggregation |
| 01/21/1999 | WO1999002547A1 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases |
| 01/21/1999 | WO1999002545A2 Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 01/21/1999 | WO1999002496A1 (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders |
| 01/21/1999 | WO1999002252A1 Improvements in or relating to capsules |
| 01/21/1999 | WO1999002189A1 Pharmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor |
| 01/21/1999 | WO1999002151A1 Paclitaxel compositions containing hyaluronic acid of a molecular weight of less than 750.000 da |
| 01/21/1999 | WO1999002147A1 Improved methods and compositions for treating male erectile dysfunction |
| 01/21/1999 | WO1999002145A1 Combination drug therapies comprising aminoglycoside antibiotics and n,n'-disubstituted guanidines |
| 01/21/1999 | WO1999002143A2 Medicament comprising adenosine |
| 01/21/1999 | WO1999002142A2 Novel composition comprising an ssri and a beta-blocker |
| 01/21/1999 | WO1999002133A2 Topical application of a combination of benzoyl peroxide and a second active ingredient |
| 01/21/1999 | WO1998048025A3 Regulatory system for inducible expression of genes with lambdoid promoters |
| 01/21/1999 | WO1998024810A3 Vertebrate homologues of unc-53 protein of c. elegans |
| 01/21/1999 | CA2295908A1 New human growth regulator protein |
| 01/21/1999 | CA2295822A1 Novel composition |
| 01/21/1999 | CA2295688A1 Agent for the treatment and/or prophylaxis of microcirculation disorders |
| 01/21/1999 | CA2295595A1 Improved methods and compositions for treating male erectile dysfunction |
| 01/21/1999 | CA2295375A1 Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 01/21/1999 | CA2295086A1 Wa545 compositions |
| 01/21/1999 | CA2292480A1 (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders |
| 01/21/1999 | CA2292451A1 Pharmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor |
| 01/20/1999 | EP0892064A2 Recombinant secA2 polypeptide from Staphylococcus aureus and uses thereof |
| 01/20/1999 | EP0892062A2 The Chlamydia trachomatis Glutamyl-tRNAGln amidotransferase subunit ratC |
| 01/20/1999 | EP0892061A2 The Chlamydia trachomatis Glutamyl-tRNAGln amidotransferase subunit ratB |